Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Oisquercq – page 136

1 851 clinical trials in Oisquercq, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Oisquercq at a glance
1 851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 851 trials in Oisquercq

Open in trial search

Study of Belzutifan for Patients with Advanced Kidney Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effects of Siplizumab in Adults with New Onset Type 1 Diabetes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Paracetamol
  • Sponsor:Itb-Med AB

Colitis ulcerative

Not recruiting

Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tilpisertib fosmecarbil
  • Sponsor:Gilead Sciences Inc.

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm malignant

Not recruiting

Study on the Long-Term Safety of Sacituzumab Govitecan for Patients with Metastatic Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Gilead Sciences Inc.

Study on the Effects of Romosozumab and Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Calcium
  • Sponsor:Amgen Inc.

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of BLU-222 Alone and with Drug Combination for Patients with Advanced Solid Tumors, Including Breast and Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BLU-222
  • Sponsor:Blueprint Medicines Corp.

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Hidradenitis

Not recruiting

Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on ARGX-117 for Improving Kidney Function in Patients with Delayed Graft Function After Deceased Donor Transplant

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Oisquercq

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on recurrent orofacial herpes infections, evaluating innovative therapeutic approaches for patients experiencing frequent outbreaks.

  • Herpes Management
  • Outbreak Prevention
  • Treatment Efficacy

The study aims to assess a new therapeutic intervention for reducing the frequency of herpes episodes through a controlled, double-blind methodology.

02 Viral Disease Control

Research examining the effectiveness of preventive treatments for patients who experience six or more herpes episodes annually.

  • Viral Suppression
  • Long-term Management
  • Quality of Life Impact

The trial evaluates treatment outcomes over a 12-month period, focusing on reducing infection recurrence rates.

03 Clinical Therapeutics

Investigation of placebo-controlled interventions designed to address recurring viral infections affecting the orofacial region.

  • Treatment Innovation
  • Symptom Control
  • Patient Response

This research emphasizes the development of effective strategies for managing frequent herpes outbreaks.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.